Press Release March 9, 2022Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis 0 0 Share
Company Ticker News March 3, 2022Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 0 0 Share
Company Ticker News March 1, 2022Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates 0 0 Share
Company Ticker News February 28, 2022ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript 0 0 Share
Company Ticker News February 28, 2022Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates 0 0 Share
Company Ticker News February 28, 2022Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results 0 0 Share
Company Ticker News February 24, 2022These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022? 0 0 Share
Company Ticker News February 22, 2022Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right 0 0 Share
Company Ticker News February 21, 2022Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know 0 0 Share
Press Release February 16, 2022Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer's Disease Psychosis 0 0 Share
